FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in approving new treatments for metastatic colorectal cancer (mCRC). Regorafenib was placed…  Read More

Regorafenib Now Available Via Expanded Access

Click Here to Get updates from Fight Colorectal Cancer The first four sites where colorectal cancer patients can get regorafenib are now open.  Bayer Healthcare expects to open additional sites in the next two or three weeks. Colorectal cancer patients whose cancer has gotten worse on all standard treatments can now be considered for the Regorafenib…  Read More

"Report from 2012 GI Cancers Symposium" Available for Viewing

Fight Colorectal Cancer has posted a recording of its February webinar, Report from the 2012 GI Cancers Symposium, held in partnership with the Colon Cancer Alliance. Each year, the best and brightest minds in gastrointestinal oncology meet to discuss the latest research into colorectal, pancreatic, esophageal and other GI cancers. The 2012 symposium offered major news…  Read More